Market Overview

Ligand Partner GSK Receives Marketing Authorization from EC for Additional Revolade Indication as Treatment for Chronic Hepatitis C-Associated Thrombocytopenia

Related LGND
Milestone Payment for Ligand Pharma - Analyst Blog
Bright Outlook at Ligand - Analyst Blog

SAN DIEGO--(BUSINESS WIRE)--

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner
GlaxoSmithKline plc (LSE:GSK) (NYSE: GSK) announced today that the
European Commission has granted an additional indication for Revolade™
(eltrombopag) as a treatment for low platelet counts (thrombocytopenia)
in adult patients with chronic hepatitis C infection, where the degree
of thrombocytopenia is the main factor preventing the initiation or
limiting the ability to maintain optimal interferon (IFN)-based therapy.1

Thrombocytopenia may prevent the initiation2 and maintenance
of peginterferon (pIFN)-based treatment, thereby reducing a patient's
chances of achieving a sustained virologic response (SVR)*3 -
the primary goal of hepatitis C treatment.

“We are extremely pleased with the decision of the European Commission,

See full press release

Posted-In: News Guidance Contracts Management Global

 

Most Popular

Related Articles (LGND + GSK)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free